10-Q: Arbutus Biopharma Secures $178.4M Moderna Settlement, Advances HBV Drug Trials

Arbutus Biopharma reports a substantial $178.4 million settlement payment from Moderna and positive clinical trial updates for its chronic hepatitis B therapeutic, imdusiran.

Summary

• Arbutus Biopharma Corporation filed its Form 10-Q for the quarterly period ended June 30, 2026.
• The company received $178.4 million as its share of a noncontingent settlement payment from Moderna related to patent litigation.
• Arbutus is advancing its chronic hepatitis B (cHBV) drug candidates, imdusiran (AB-729) and AB-101.
• Clinical trial data for imdusiran showed promising results, with some patients achieving functional cure or remaining off NA therapy.
• The company continues to defend its intellectual property, including ongoing lawsuits against Pfizer/BioNTech.
• Arbutus had $92.6 million in cash, cash equivalents, and marketable securities as of June 30, 2026, with no outstanding debt.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this filing positively due to the significant settlement payment received from Moderna and the ongoing progress in clinical trials for imdusiran, despite ongoing litigation.

Positives

• Received $178.4 million from Moderna as a noncontingent settlement payment on July 8, 2026.
• Moderna is obligated to pay an additional contingent settlement payment of up to $1.3 billion.
• Imdusiran (AB-729) showed positive results in Phase 2a trials, with 47% of patients achieving functional cure or remaining off NA therapy.
• FDA granted Fast Track designation for imdusiran in April 2026.
• Alignment reached with the FDA on the design and safety parameters for a proposed Phase 2b clinical trial for imdusiran.
• Cash, cash equivalents, and marketable securities totaled $92.6 million as of June 30, 2026, with no outstanding debt.
• The company anticipates a material dividend from Genevant in Q3 2026.
• Arbutus is evaluating a return of capital to shareholders in Q3 2026.

Negatives

• Net loss of $5.143 million for the three months ended June 30, 2026, compared to a net income of $2.523 million in the prior year period.
• Research and development expenses decreased due to study completions, which could indicate a slowdown in active development for some programs.
• The European Patent Office revoked European patent EP 2279254, though Arbutus plans to appeal.
• Two patients who achieved functional cure seroreverted during long-term follow-up, though remained virally suppressed and off NA therapy.

Risks

• Ongoing patent infringement lawsuits against Pfizer/BioNTech and the United States.
• The outcome of the Moderna 1498 Appeal could impact the contingent settlement payment.
• Potential repayment of the contingent settlement payment to Moderna under certain circumstances.
• The success of operations is dependent on obtaining necessary regulatory approvals and achieving profitability.
• It is not possible to predict the outcome of development programs or the ability to continue funding them.
• The company may need to seek additional funding, and there is no assurance it will be available on acceptable terms.
• The European Patent Office revoked European patent EP 2279254, and Arbutus is awaiting a written decision to file a petition for review.
• The company's development activities and commercialization of products are dependent on its ability to obtain adequate financing.

Future Outlook

The company believes it has sufficient cash resources to fund operations for at least the next 12 months. Future funding needs will depend on patent prosecution costs, potential return of capital, revenue from partnerships, development costs, and regulatory decisions. Arbutus is evaluating a return of capital to shareholders in Q3 2026.

Management Comments

• The company believes it has sufficient cash resources to fund its operations for at least the next 12 months.
• The success of the Company's operations is dependent on obtaining the necessary regulatory approvals to bring one or more of its product candidates to market and achieve profitability from ongoing operations.
• It is not possible to predict either the outcome of the Company's existing or future development programs or the Company's ability to continue to fund these programs in the future.

Industry Context

StockSavvy.ai notes that Arbutus operates in the highly competitive biopharmaceutical sector, focusing on infectious diseases, specifically chronic hepatitis B. The significant settlement from Moderna highlights the value and contentious nature of intellectual property in the mRNA vaccine space. The company's progress in clinical trials for imdusiran positions it within the ongoing efforts to find a functional cure for HBV, a market with significant unmet needs.

Comparison to Industry Standards

• The functional cure rate for imdusiran in Phase 2a trials (25-50% in specific cohorts) is a key metric. Achieving functional cure (sustained HBsAg seroclearance and HBV DNA <LLOQ off treatment) is the industry goal for HBV therapies.
• The ability of 47% of Phase 2a patients to remain off NA therapy for at least 48 weeks after discontinuing NA therapy following imdusiran treatment is a positive indicator, as current NA therapies require lifelong treatment.
• The Fast Track designation for imdusiran by the FDA aligns with industry trends of expediting promising therapies for serious conditions with unmet medical needs.
• The $178.4 million received from Moderna is a substantial amount, reflecting the high stakes and value of intellectual property in the biopharmaceutical industry, particularly concerning widely adopted technologies like LNP delivery systems.

Legal Proceedings

• Ongoing patent infringement lawsuits against Pfizer/BioNTech in the US and internationally.
• Lawsuit against the United States in the Court of Federal Claims.
• Moderna LNP Litigation resolved by settlement, with an ongoing appeal (Moderna 1498 Appeal).
• European patent EP 2279254 was revoked by the EPO Board of Appeal; Arbutus plans to appeal.
• Revocation actions against European patent EP 4241767 filed by Moderna and Merck, with Moderna and Merck withdrawing from proceedings.
• Other legal matters arising in the ordinary course of business, not expected to have a material adverse effect.

Related Party Transactions

• The company owns approximately 16% of Genevant Sciences Ltd. (a related party).
• Moderna Settlement Agreement involved Arbutus and Genevant receiving payments from Moderna.
• Genevant paid Arbutus a $1.0 million termination fee related to the RSV Agreement.

Stakeholder Impact

• Shareholders benefit from the significant settlement payment from Moderna and potential return of capital.
• Patients with chronic hepatitis B may benefit from the continued development of imdusiran and AB-101, potentially leading to new treatment options.
• Employees may be impacted by ongoing restructuring and focus on core development programs.
• Creditors are not directly impacted as the company has no outstanding debt.

Next Steps

• Continue patent infringement litigation against Pfizer/BioNTech.
• Await further scheduling in the Pfizer/BioNTech litigation.
• Evaluate a potential return of capital to shareholders in Q3 2026.
• Anticipate payment of a material dividend from Genevant in Q3 2026.
• Incorporate FDA feedback into a final Phase 2b protocol for imdusiran.
• Continue development of imdusiran and AB-101 for chronic hepatitis B.

Key Dates

Recommendation

The significant settlement payment from Moderna provides a strong financial cushion and de-risks the company's near-term liquidity. Positive clinical data for imdusiran is encouraging. However, the ongoing patent litigation against Pfizer/BioNTech, the uncertainty surrounding the contingent settlement payment from Moderna, and the inherent risks in biopharmaceutical development warrant a cautious 'hold' rating. Investors should monitor the progress of clinical trials and the outcomes of ongoing legal proceedings.

Keywords

Hepatitis B, RNAi, Imdusiran, LNP technology, Patent litigation, Moderna settlement, Clinical trials, Biopharmaceutical